Cleared Traditional

MaxiTears Contacts PF (K182984) - FDA 510(k) Clearance

Class II Ophthalmic device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K182984 · Omnivision AG · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2019
Decision
268d
Days
Class 2
Risk

K182984 is an FDA 510(k) clearance for the MaxiTears Contacts PF. Classified as Products, Contact Lens Care, Rigid Gas Permeable (product code MRC), Class II - Special Controls.

Submitted by Omnivision AG (Neuhausen Am Rheinfall, CH). The FDA issued a Cleared decision on July 24, 2019 after a review of 268 days - an extended review cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.5918 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Ophthalmic review framework, consistent with the majority of Class II 510(k) submissions.

View all Omnivision AG devices

Submission Details

510(k) Number K182984 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 29, 2018
Decision Date July 24, 2019
Days to Decision 268 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
158d slower than avg
Panel avg: 110d · This submission: 268d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code MRC Products, Contact Lens Care, Rigid Gas Permeable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.5918
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.

Regulatory Consultant

Emergo Global Consulting, LLC
Oliver Eikenberg

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - MRC Products, Contact Lens Care, Rigid Gas Permeable

All 32
Devices cleared under the same product code (MRC) and FDA review panel - the closest regulatory comparables to K182984.
cleadew GP hydra one
K251876 · Ophtecs Corporation · Oct 2025
Boston One Step Liquid Enzymatic Cleaner
K200416 · Bausch & Lomb, Incorporated · Sep 2020
VibrantVue Scleral Saline
K201069 · Dry Eye Innovations, LLC · Jul 2020
Nutrifill
K181566 · Contamac, Ltd. · Oct 2018
Bausch + Lomb Boston SimplusMulti-Action Solution, Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner
K181627 · Bausch & Lomb, Incorporated · Aug 2018
Bausch + Lomb Boston Advance Cleaner, Bausch + Lomb Boston Advance Conditioning Solution
K180319 · Bausch and Lomb, Incorporated · Mar 2018